Skip to main content
Equibles
AGIO logo

AGIO · Agios Pharmaceuticals, Inc. · Analyst Estimates

Track AGIO — free

Use AGIO with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research AGIO.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$38.03 +1.18 (+3.20%) At close · Oct 27 Q2 2026 earnings call transcript
Russell 2000 member Rebalance outlook locked
Market Cap
$2.27B
Shares
59.70M
Volume · Oct 27 739.1K Avg daily vol (3M) 1.09M

Analyst Estimates

Compare analyst forecasts for Agios Pharmaceuticals, Inc. across metrics and forecast periods.

Estimates are grouped by forecast period, with low, average and high together. A dash means that statistic is not available.

Compiled consensus

These figures are a compiled consensus of analyst forecasts, not a survey the company published itself. Every figure is the statistic the source states; averages are means, never medians.

Captured 2026-10-23 01:08 UTC · Publication dates shown per estimate · 8 metric / period groups

FY ending 2026-12-31

Analyst estimates for FY ending 2026-12-31
Metric Low Average High Analyst count Average, 7 days ago Average, 30 days ago Average, 60 days ago Average, 90 days ago Estimates lowered, last 7 days Estimates lowered, last 30 days Estimates raised, last 7 days Estimates raised, last 30 days
EPS
USD
Publication date not stated
-6.68
-5.74
-5.28
8
-5.72
-5.63
-5.63
-6.21
3
3
0
0
Revenue
USD
Publication date not stated
166.00M
176.72M
186.37M
10
 — — — — — — — —

FY ending 2027-12-31

Analyst estimates for FY ending 2027-12-31
Metric Low Average High Analyst count Average, 7 days ago Average, 30 days ago Average, 60 days ago Average, 90 days ago Estimates lowered, last 7 days Estimates lowered, last 30 days Estimates raised, last 7 days Estimates raised, last 30 days
EPS
USD
Publication date not stated
-4.90
-3.77
-2.12
10
-3.74
-3.70
-3.69
-4.65
3
3
0
0
Revenue
USD
Publication date not stated
222.05M
345.35M
428.14M
10
 — — — — — — — —

Q ending 2026-09-30

Analyst estimates for Q ending 2026-09-30
Metric Low Average High Analyst count Average, 7 days ago Average, 30 days ago Average, 60 days ago Average, 90 days ago Estimates lowered, last 7 days Estimates lowered, last 30 days Estimates raised, last 7 days Estimates raised, last 30 days
EPS
USD
Publication date not stated
-1.64
-1.23
-1.06
8
-1.22
-1.19
-1.19
-1.48
3
3
0
0
Revenue
USD
Publication date not stated
47.00M
51.50M
55.38M
10
 — — — — — — — —

Q ending 2026-12-31

Analyst estimates for Q ending 2026-12-31
Metric Low Average High Analyst count Average, 7 days ago Average, 30 days ago Average, 60 days ago Average, 90 days ago Estimates lowered, last 7 days Estimates lowered, last 30 days Estimates raised, last 7 days Estimates raised, last 30 days
EPS
USD
Publication date not stated
-1.66
-1.14
-0.79
10
-1.12
-1.08
-1.08
-1.40
1
1
1
1
Revenue
USD
Publication date not stated
52.90M
59.68M
65.80M
10
 — — — — — — — —
Key facts CIK 1439222 CUSIP 00847X104 13F (30d) 35 filings 35 filers Visit website Investor relations